Table 1. Characteristics of patients who underwent HLA identical sibling allogeneic transplant or HLA matched unrelated donor allogeneic transplant for follicular lymphoma from 2001-2011, by registry.
| Total N (%) | CIBMTR N (%) | EBMT N (%) | P-value | |
|---|---|---|---|---|
| Number of patients | 1567 | 452 | 1115 | |
| Patient age at transplant, years | 0.062 | |||
| Median | 51 (21-74) | 50 (21-74) | 51 (24-72) | |
| 21-30 | 24 (2) | 12 (3) | 12 (1) | |
| 31-40 | 204 (13) | 67 (15) | 137 (12) | |
| 41-50 | 586 (37) | 155 (34) | 431 (39) | |
| 51-60 | 592 (38) | 175 (39) | 417 (37) | |
| ≥61 | 161 (10) | 43 (10) | 118 (11) | |
| Gender | 0.064 | |||
| Male | 935 (60) | 286 (63) | 649 (58) | |
| Female | 632 (40) | 166 (37) | 466 (42) | |
| Karnofsky score | <0.001 | |||
| <80 | 56 (4) | 35 (8) | 21 (2) | |
| ≥80 | 1005 (64) | 392 (87) | 613 (55) | |
| Missing | 506 (32) | 25 (6) | 481 (43) | |
| Disease-related | ||||
| Histology | <0.001 | |||
| Grade 1 | 455 (29) | 187 (41) | 268 (24) | |
| Grade 2 | 389 (25) | 163 (36) | 226 (20) | |
| Grade 3 | 319 (20) | 84 (19) | 235 (21) | |
| Unknown grade | 404 (26) | 18 (4) | 386 (35) | |
| Number of prior chemotherapy regimens | <0.001 | |||
| 1-2 | 291 (19) | 102 (23) | 189 (17) | |
| 3-4 | 397 (25) | 225 (50) | 172 (15) | |
| ≥5 | 172 (11) | 97 (21) | 75 (7) | |
| Missing number of previous regimens | 707 (45) | 28 (6) | 679 (61) | |
| Previous ASCT | 456 (29) | 53 (12) | 403 (36) | <0.001 |
| Interval ASCT-allo-HCT, median (range), months | 26 (1-249) | 19 (1-101) | 27 (6-249) | 0.001 |
| Disease stage at diagnosis | <0.001 | |||
| I-II | 121 (8) | 61 (13) | 60 (5) | |
| III-IV | 816 (52) | 359 (79) | 457 (41) | |
| Not available | 630 (40) | 32 (7) | 598 (54) | |
| Disease status at HCT | <0.001 | |||
| PIF sensitive | 63 (4) | 63 (14) | 0 | |
| PIF resistant | 138 (9) | 43 (10) | 95 (9) | |
| REL sensitive | 457 (29) | 139 (31) | 318 (29) | |
| REL resistant | 73 (5) | 70 (15) | 3 (<1) | |
| CR2+ | 452 (29) | 89 (20) | 363 (33) | |
| REL untreated/unknown | 315 (20) | 16 (4) | 299 (27) | |
| PIF unknown | 3 (<1) | 2 (<1) | 1 (<1) | |
| Not available | 66 (4) | 30 (7) | 36 (3) | |
| Response to therapy immediately prior to HCT | <0.001 | |||
| Sensitive | 1192 (76) | 307 (68) | 885 (79) | |
| Resistant | 258 (16) | 113 (25) | 145 (13) | |
| Unknown | 117 (7) | 32 (7) | 85 (8) | |
| Transplant-related | ||||
| Interval diagnosis to allo-HCT, median (range), months | 47 (3-363) | 42 (3-352) | 51 (4-363) | <0.001 |
| Rituximab at conditioning | 154 (10) | 92 (20) | 62 (6) | <0.001 |
| Conditioning regimens | <0.001 | |||
| Myeloablative (MA) | 365 (23) | 145 (32) | 220 (20) | |
| RIC/NMA | 1202 (77) | 307 (68) | 895 (80) | |
| Conditioning regimens | <0.001 | |||
| MAC | ||||
| TBI+Cy | 155 (10) | 79 (17) | 76 (7) | |
| BEAM ± others | 56 (4) | 4 (1) | 52 (5) | |
| Bu ± others | 51 (3) | 32 (7) | 19 (2) | |
| Bu+Cy | 40 (3) | 23 (5) | 17 (2) | |
| Fludarabine ± others | 16 (1) | 0 | 16 (1) | |
| TBI+Fludarabine | 8 (1) | 0 | 8 (1) | |
| Others | 39 (2) | 7 (2) | 32 (3) | |
| RIC | ||||
| Fludarabine+Melphalan | 303 (19) | 46 (10) | 257 (23) | |
| Bu ± Fludarabine | 196 (13) | 69 (15) | 127 (11) | |
| Cy+Thiotepa | 37 (2) | 0 | 37 (3) | |
| Melphalan+Cy | 19 (1) | 11 (2) | 8 (1) | |
| CCNU ± others | 11 (1) | 3 (1) | 8 (1) | |
| TBI+Cy | 10 (1) | 9 (2) | 1 (<1) | |
| Others | 29 (2) | 10 (2) | 19 (2) | |
| NMA | ||||
| TBI+Fludarabine | 226 (14) | 40 (9) | 186 (17) | |
| Fludarabine+Cy | 216 (14) | 113 (25) | 103 (9) | |
| TBI +/- Cy | 33 (2) | 4 (1) | 29 (3) | |
| Others | 122 (8) | 2 (<1) | 120 (11) | |
| Donor type | <0.001 | |||
| HLA-matched siblings | 1148 (73) | 285 (63) | 863 (77) | |
| Unrelated well matched | 419 (27) | 167 (37) | 252 (23) | |
| D-R CMV status | <0.001 | |||
| Any Positive | 885 (56) | 302 (67) | 583 (52) | |
| All negative | 381 (24) | 137 (30) | 244 (22) | |
| Missing | 301 (19) | 13 (3) | 288 (26) | |
| D-R sex match | 0.427 | |||
| M-M & F-F | 847 (54) | 248 (55) | 599 (54) | |
| M-F | 338 (22) | 86 (19) | 252 (23) | |
| F-M | 365 (23) | 113 (25) | 252 (23) | |
| Missing | 17 (1) | 5 (1) | 12 (1) | |
| Source of stem cells | 0.767 | |||
| Bone marrow | 154 (10) | 46 (10) | 108 (10) | |
| Peripheral blood | 1413 (90) | 406 (90) | 1007 (90) | |
| Year of transplant | <0.001 | |||
| 2001-2003 | 380 (24) | 150 (33) | 230 (21) | |
| 2004-2006 | 411 (26) | 123 (27) | 288 (26) | |
| 2007-2009 | 499 (32) | 135 (30) | 364 (33) | |
| 2010-2011 | 277 (18) | 44 (10) | 233 (21) | |
| ATG-Campath | <0.001 | |||
| ATG alone | 4 (1) | 0 | 4 (<1) | |
| Campath alone | 248 (16) | 60 (13) | 188 (17) | |
| ATG+Campath | 229 (14) | 29 (6) | 200 (18) | |
| None | 352 (22) | 352 (78) | 0 | |
| Missing | 734 (47) | 11 (2) | 723 (65) | |
| GVHD prophylaxis | <0.001 | |||
| CNI+MTX | 360 (23) | 61 (13) | 299 (27) | |
| CNI+MMF | 318 (20) | 42 (9) | 276 (25) | |
| CNI± other | 608 (39) | 334 (74) | 274 (24) | |
| Others/missing | 281 (18) | 15 (3) | 266 (24) | |
| Follow-up of survivors, median (range), months | 55 (3-160) | 58 (3-130) | 54 (3-160) |
EBMT = European Group for Blood and Marrow Transplantation; CIBMTR = Center for International Blood and Bone Marrow Transplant Research; ASCT = Autologous stem Cell Transplantation; Allo-HCT = Allogeneic Hematopoietic Transplantation; BuCy = Busulfan Cyclophosphamide; BEAM = BCNU, etoposide, cytarabine, melphalan; CBV = Cyclophosphamide, BCNU, etoposide; TBI = Total Body Irradiation; RIC = reduced intensity conditioning; NST = non-myeloablative transplant; Mel = Melphalan; M = Male; F = Female; CMV = Cytomegalovirus; GVHD = graft versus host disease; MTX = methotrexate; CsA = cyclosporine; MMF = Mycophenolatemofetil; FK506 = tacrolimus.
*
Other GVHD prophylaxis: MTX alone (n=14); MMF alone (n=13) and not specified (n=254)